4SC 2010 first nine months revenue decreases from EUR1.

Pending acceptance from all regulatory authorities, a Phase I medical study in hematological tumours will commence this season to check this drug candidate, which has a focus on profile that differs substantially from that of resminostat . Outlook: 4SC expects to meet up further important milestones in clinical development and to be able to deliver […]

Read More

Akonni receives NSFs Phase 2 SBIR Grant to develop Lab-on-a-Film microarray Akonni Biosystems.

Christopher Cooney, Principal Investigator on the director and grant of Engineering in Akonni Biosystems. ‘The advantage of this manufacturing approach is that Lab-on-a-Film microarray production and assembly could be automated at very high speeds, resulting in ten – to one hundred-fold savings in consumable costs.’ Related StoriesUCSF-led researchers map out melanoma's genetic trajectoriesNew clinical trial […]

Read More

Ola Landgren.

For individuals with a latency of 32 months or much less, the mutational status of IGHV was described in 21 of 27 sufferers. Of the patients, 16 got mutated genes, and 5 experienced unmutated genes. The distribution of the current presence of IGHV was comparable in the two groups . Whenever we assessed patterns of […]

Read More